search results for

refine results

sort by


result type


Press Releases

All leaders have to speak to things that are right and wrong: Former Onyx Pharma CEO

Tony Coles, Yumanity Therapeutics CEO and former Onyx Pharma CEO, discusses the impact of Merck CEO Ken Frazier's leaving President Trump's Manufacturing Council. CNBC's Meg Tirrell weighs in.


Merck has more manufacturing employees in US than overseas

CNBC's Meg Tirrell reports on President Trump's attacks on Merck's CEO Ken Frazier after he left the WH Manufacturing Council.


Trump doesn't 'know the facts' when he says Merck is shipping jobs overseas

The president may want to check his facts on Merck, which he accused of "taking jobs out of the U.S."


Bristol-Myers falls on kidney cancer drug trial results

CNBC's Meg Tirrell reports on Bristol-Myers falling after its kidney cancer drug trial results. Also, more on Merck's CEO's decision to leave the President's manufacturing council.


Merck CEO Ken Frazier focused on justice even before WH council resignation

After Merck CEO Ken Frazier announced his resignation from the president's manufacturing council, CNBC's Meg Tirrell reports on Frazier's previous fights for justice.


Amid corporate career, Merck CEO exonerated man on death row

Frazier said the experience showed him "why there can be no fair and consistent application of the death penalty under the current system."


Merck shares up despite Trump's tweet attack

CNBC's Meg Tirrell reports on the resignation of Merck CEO Ken Frazier from the president's White House council.


Biotech is tracking for its worst month of the year & here's how much worse it could get

CNBC's Meg Tirrell discusses the biotech sector's worst day since January and what is driving the dip. The “Fast Money” traders weigh in.


Here's why competitiveness in generic drug market is at risk: Industry expert

CNBC's Meg Tirrell speaks with Chip Davis, Association for Accessible Medicines president, about generic drugs facing pricing pressures.


Mylan to defer 2 major U.S. drug launches to 2018

CNBC's Meg Tirrell reports Mylan shares are under pressure after reporting weaker than expected earnings.